Results 151 to 160 of about 2,409,493 (295)

Lipid peroxidation-induced DNA adducts in human gastric mucosa.

Carcinogenesis, 2013
T. Matsuda, H. Tao, Masanori Goto, Hidetaka Yamada, Masaya Suzuki, Yijia Wu, Nong Xiao, Qiong He, Wenwen Guo, Zhenming Cai, Nobuya Kurabe, K. Ishino, Y. Matsushima, K. Shinmura, H. Konno, M. Maekawa, Yaping Wang, H. Sugimura   +17 more
semanticscholar   +1 more source

Cannabigerol reverses mechanical allodynia through α2A‐adrenergic modulation of thalamocortical signaling in chemotherapy‐induced neuropathy

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Chemotherapy‐induced peripheral neuropathy (CIPN) is a prevalent and treatment‐resistant side effect of platinum‐based chemotherapy, characterised by mechanical allodynia. Cannabigerol (CBG), a non‐psychoactive cannabinoid, has shown antinociceptive potential, but its site and mechanism of action remain unclear.
Quinn W. Wade, Nathan Morris, Diana E. Sepulveda, Alonso Cortez‐Resendiz, Christopher Brandl, Jennifer E. Lausch, Mariya Starostina, Nicholas M. Graziane   +7 more
wiley   +1 more source

A simplified LC-MS-based method for sensitive analysis of DNA adducts utilizing accessible in vitro metabolism models. [PDF]

Arch Toxicol
Gerdemann A, Behrens M, Günther G, Ghallab A, Hengstler JG, Humpf HU, Esselen M.   +6 more
europepmc   +1 more source

Quantitation of DNA Adducts Resulting from Acrolein Exposure and Lipid Peroxidation in Oral Cells of Cigarette Smokers from Three Racial/Ethnic Groups with Differing Risks for Lung Cancer. [PDF]

Chem Res Toxicol, 2022
Park SL, Le Marchand L, Cheng G, Balbo S, Chen M, Carmella SG, Thomson NM, Lee Y, Patel YM, Stram DO, Jensen J, Hatsukami DK, Murphy SE, Hecht SS.   +13 more
europepmc   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

Effect of methyl DNA adducts on 3'-5' exonuclease activity of human TREX1. [PDF]

Biochem J
Tuti N, Shaji UP, Das S, Anindya R.
europepmc   +1 more source

Feeding Brassica vegetables to rats leads to the formation of characteristic DNA adducts (from 1-methoxy-3-indolylmethyl glucosinolate) in many tissues. [PDF]

Arch Toxicol, 2022
Glatt H, Engst W, Florian S, Schreiner M, Baasanjav-Gerber C.   +4 more
europepmc   +1 more source

Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid.

Kidney International, 2012
B. Jelaković, S. Karanovic, Ivana Vuković-Lela, Frederick Miller, K. Edwards, J. Nikolic, K. Tomić, N. Slade, B. Brdar, R. Turesky, Ž. Stipančić, D. Dittrich, A. Grollman, K. Dickman   +13 more
semanticscholar   +1 more source

Targeting protein–protein interactions with reversible covalent modalities: Non‐cysteine chemistries

British Journal of Pharmacology, EarlyView.
Abstract Protein–protein interactions (PPIs) are central to diverse cellular functions, and represent a rapidly expanding class of therapeutic targets. Advancements in covalent drug design have enabled small‐molecule drugs to overcome challenges associated with engaging these targets, such as limited durations of action and difficult‐to‐drug (expansive,
Ruchira Basu, Steven Fletcher
wiley   +1 more source

DNA adducts form in mouse lung and liver after oral naphthalene exposure. [PDF]

Toxicol Sci
Domanico MC, Collette NM, Ubick E, Ding X, Buchholz BA, Van Winkle LS.   +5 more
europepmc   +1 more source